NEW CASTLE, Del., Sept. 6, 2012 (GLOBE NEWSWIRE) -- ScripsAmerica Inc. (OTCBB:SCRC), a leading supplier of prescription, OTC and nutraceutical drugs, today announced that Elsevier, the world's leading publisher of science and health information, profiled the Company in its publication "The Tan Sheet" on Friday, August 24th, 2012.
"The Tan Sheet" provides professionals and consumers in the pharmaceutical and dietary supplement industries with in-depth coverage of news related to companies that produce nonprescription pharmaceuticals and nutraceuticals. The feature article, titled "ScripsAmerica's RapiMed Painkillers Will Go Up Against Tylenol Meltaways," highlights ScripsAmerica's RapiMed line of orally dissolving pediatric pain relievers and its proprietary formulation that promises to melt faster, taste better and cost less than the current market leader, Tylenol Meltaways, as well as addresses FDA dosing concerns.
"ScripsAmerica is very excited to be featured in the Tan Sheet, a publication that reaches market leaders, scientists and health and information professionals worldwide. We believe that being covered by a publishing company with the reputation, quality readership and industry reach of Elsevier shows the potential of our RapiMed line to have a great impact on the pediatric pain relief market due to its faster delivery, better taste and convenient packaging," commented ScripsAmerica's CEO, Bob Schneiderman.
About Elsevier Inc.
Elsevier is a global company headquartered in Amsterdam, employing more than 7,000 people in 24 countries. As the world's leading publisher of science and health information, Elsevier serves an audience of more than 30 million industry professionals worldwide. The company is known for providing the latest information, innovative products and tools to its customers, helping them make critical decisions, enhance productivity and improve bottom line results in an ever-changing environment.
For more information about Elsevier and "The Tan Sheet" please visit www.elsevier.com.
About ScripsAmerica, Inc.
ScripsAmerica, Inc. delivers pharmaceutical products to a wide range of end users across the health care industry, including physicians' offices, retail pharmacies, long-term care sites, hospitals, and Government and home care agencies through the largest pharmaceutical distributor in North America, McKesson Corporation. Current therapeutic categories serviced by the Company include pain, arthritis, prenatal, urinary, and hormonal replacement drugs. Other customers of ScripsAmerica include Cardinal Health, Curtis Pharmaceuticals, MedVet and the United States Veterans Administration.
For more information please visit: www.ScripsAmerica.com.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.